Hanall Biopharma - Asset Resilience Ratio
Hanall Biopharma (009420) has an Asset Resilience Ratio of 3.91% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 009420 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Hanall Biopharma's Asset Resilience Ratio has changed over time. See 009420 net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hanall Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 009420 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩8.32 Billion | 3.91% |
| Total Liquid Assets | ₩8.32 Billion | 3.91% |
Asset Resilience Insights
- Limited Liquidity: Hanall Biopharma maintains only 3.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hanall Biopharma Industry Peers by Asset Resilience Ratio
Compare Hanall Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Haleon plc
NYSE:HLN |
Drug Manufacturers - Specialty & Generic | 4.06% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.62% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601 |
Drug Manufacturers - Specialty & Generic | 12.24% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
Annual Asset Resilience Ratio for Hanall Biopharma (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Hanall Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.91% | ₩8.32 Billion ≈ $5.64 Million |
₩212.88 Billion ≈ $144.27 Million |
-5.59pp |
| 2023-12-31 | 9.50% | ₩22.77 Billion ≈ $15.43 Million |
₩239.75 Billion ≈ $162.47 Million |
-7.88pp |
| 2022-12-31 | 17.38% | ₩37.09 Billion ≈ $25.14 Million |
₩213.45 Billion ≈ $144.65 Million |
-16.77pp |
| 2021-12-31 | 34.15% | ₩67.78 Billion ≈ $45.93 Million |
₩198.48 Billion ≈ $134.51 Million |
-5.15pp |
| 2020-12-31 | 39.30% | ₩86.51 Billion ≈ $58.62 Million |
₩220.13 Billion ≈ $149.18 Million |
-7.37pp |
| 2019-12-31 | 46.67% | ₩89.31 Billion ≈ $60.53 Million |
₩191.38 Billion ≈ $129.70 Million |
+5.59pp |
| 2018-12-31 | 41.08% | ₩66.67 Billion ≈ $45.18 Million |
₩162.30 Billion ≈ $109.99 Million |
+9.26pp |
| 2017-12-31 | 31.82% | ₩53.67 Billion ≈ $36.37 Million |
₩168.70 Billion ≈ $114.32 Million |
-4.62pp |
| 2016-12-31 | 36.43% | ₩45.44 Billion ≈ $30.80 Million |
₩124.73 Billion ≈ $84.53 Million |
+3.16pp |
| 2015-12-31 | 33.28% | ₩38.98 Billion ≈ $26.41 Million |
₩117.13 Billion ≈ $79.37 Million |
+26.11pp |
| 2014-12-31 | 7.17% | ₩6.25 Billion ≈ $4.23 Million |
₩87.17 Billion ≈ $59.07 Million |
+0.16pp |
| 2013-12-31 | 7.01% | ₩6.86 Billion ≈ $4.65 Million |
₩97.85 Billion ≈ $66.31 Million |
-12.27pp |
| 2012-12-31 | 19.27% | ₩23.95 Billion ≈ $16.23 Million |
₩124.27 Billion ≈ $84.22 Million |
+11.34pp |
| 2011-12-31 | 7.93% | ₩8.36 Billion ≈ $5.67 Million |
₩105.46 Billion ≈ $71.47 Million |
-- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more